Dr. Goetz on Adjuvant Capecitabine Following Neoadjuvant Chemotherapy and Surgery
December 10th 2015
Matthew Goetz, MD, medical oncologist, professor of Oncology, associate professor of Pharmacology, andprofessor of Pharmacology at Mayo Clinic, discusses a phase III study looking at capecitabine (Xeloda) in patients with residual breast cancer following neoadjuvant chemotherapy and surgery.